NHS National Generic Pharmaceuticals Transition 2021_1

A Contract Award Notice
by THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)

Source
Find a Tender
Type
Framework (Goods)
Duration
14.5 month (est.)
Value
£1
Sector
HEALTH
Published
29 Apr 2021
Delivery
15 Apr 2021 to 30 Jun 2022 (est.)
Deadline
n/a

Concepts

Location

United Kingdom: Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points

Geochart for 1 buyers and 39 suppliers

1 buyer

20 suppliers

Description

Transition and 33 % products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).The total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months).

Lot Division

1 Transition 2021_1 - 100% Products (All regions)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments
2 Transition 2021_1 - CESW region (Transition & 33% products)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments
3 Transition 2021_1 - LSNE region (Transition & 33% products)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months)
4 Transition 2021_1 - NWLN region (Transition & 33% products)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments

Award Detail

1 Ascend Laboratories (Edgware)
  • Transition 2021_1 - 100% Products (All regions)
  • Reference: 009271-2021-1
  • Value: £1
2 Aspire Pharma (Petersfield)
  • Transition 2021_1 - 100% Products (All regions)
  • Reference: 009271-2021-2
  • Value: £1
3 Brown & Burk (Uxbridge)
  • Transition 2021_1 - 100% Products (All regions)
  • Reference: 009271-2021-3
  • Value: £1
4 Day Lewis Medical (Croydon)
  • Transition 2021_1 - 100% Products (All regions)
  • Reference: 009271-2021-4
  • Value: £1
5 Martindale Pharma (High Wycombe)
  • Transition 2021_1 - 100% Products (All regions)
  • Reference: 009271-2021-5
  • Value: £1
6 Panpharma (Liverpool)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-6
  • Value: £1
7 Aventis Pharma (Reading)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-7
  • Value: £1
8 Medac Pharma (Sterling)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-8
  • Value: £1
9 Aspen Pharma Ireland (Maidenhead)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-9
  • Value: £1
10 Kent Pharma (Ashford)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-10
  • Value: £1
11 Aspire Pharma (Petersfield)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-11
  • Value: £1
12 Day Lewis Medical (Croydon)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-12
  • Value: £1
13 Morningside Pharmaeuticals (Loughborough)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-13
  • Value: £1
14 Pfizer (Tadworth)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-14
  • Value: £1
15 Teva (Castleford)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-15
  • Value: £1
16 Tillomed Laboratories (Luton)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-16
  • Value: £1
17 Thornton & Ross (Huddersfield)
  • Transition 2021_1 - CESW region (Transition & 33% products)
  • Reference: 009271-2021-17
  • Value: £1
18 Accord (Barnstaple)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-18
  • Value: £1
19 Medac Pharma (Sterling)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-19
  • Value: £1
20 Amarox (Harrow)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-20
  • Value: £1
21 Drreddys Laboratories (Beverley)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-21
  • Value: £1
22 Aspen Pharma Ireland (Maidenhead)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-22
  • Value: £1
23 Morningside Pharmaeuticals (Loughborough)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-23
  • Value: £1
24 Teva (Castleford)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-24
  • Value: £1
25 Kent Pharma (Ashford)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-25
  • Value: £1
26 Panpharma (Liverpool)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-26
  • Value: £1
27 Pfizer (Tadworth)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-27
  • Value: £1
28 Selective Supplies (Haywards Heath)
  • Transition 2021_1 - LSNE region (Transition & 33% products)
  • Reference: 009271-2021-28
  • Value: £1
29 Accord (Barnstaple)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-29
  • Value: £1
30 Aspen Pharma Ireland (Maidenhead)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-30
  • Value: £1
31 Medac Pharma (Sterling)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-31
  • Value: £1
32 Drreddys Laboratories (Beverley)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-32
  • Value: £1
33 Kent Pharma (Ashford)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-33
  • Value: £1
34 Day Lewis Medical (Croydon)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-34
  • Value: £1
35 Morningside Pharmaeuticals (Loughborough)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-35
  • Value: £1
36 Panpharma (Liverpool)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-36
  • Value: £1
37 Pfizer (Tadworth)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-37
  • Value: £1
38 Ranbaxy (Hayes)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-38
  • Value: £1
39 Teva (Castleford)
  • Transition 2021_1 - NWLN region (Transition & 33% products)
  • Reference: 009271-2021-39
  • Value: £1

Award Criteria

price _

CPV Codes

  • 33600000 - Pharmaceutical products
  • 33690000 - Various medicinal products

Indicators

  • Options are available.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **

Reference

Domains